Nazara extends timeline for USD 100.3M fund infusion into UK subsidiary

Strategic Transactions View source PDF Explain this filing

NAZARA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.5%Reaction day

₹301.00

prior close

₹305.00

announcement price

After-mkt

timing

Nifty Microcap 250market+1.1%-1.6% vs market

Entertainment peers, median of 52sector · industry level-0.1%-0.4% vs sector

On the reaction day the stock moved 1.6 pts less than Nifty Microcap 250 and 0.4 pts less than its Entertainment peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.0

10m

-0.7

15m

-1.2

30m

-1.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.5+1.1-1.6-0.1-0.4

Next day

-0.5+1.6-2.1+0.3-0.8

-1.3+2.4-3.7+0.5-1.8

-0.2+3.3-3.4+1.7-1.9

-3.0+2.5-5.5+0.0-3.0

-3.2+2.4-5.6-0.4-2.8

+0.9+1.5-0.6-2.5+3.5

15d

+1.0+2.6-1.6-3.2+4.1

+1.0+2.2-1.2-3.4+4.4

+16.0+6.8+9.2-5.3+21.3

+21.3+5.9+15.4-8.2+29.5

UpDownMarket · Nifty Microcap 250Sector · Entertainment peers, median of 52Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Nazara Technologies has extended the timeline for infusing up to USD 100.3 million into its wholly owned UK subsidiary, Nazara Technologies UK Limited. The infusion, originally disclosed on March 18, 2026, will be done in one or more tranches via equity subscription (up to USD 40.1M) and a loan (up to USD 60.2M). The new indicative deadline is August 14, 2026, subject to applicable laws.

Likely market impact

Routine procedural update. Delays fund deployment into UK arm but subsidiary remains fully owned. No material impact on shareholders for now.